Enrique Soto Perez de Celis, Associate Professor at University of Colorado Anschutz, shared on LinkedIn:
“Excited to share our new paper on DPYD pharmacogenetic variation in Mexican patients with gastrointestinal cancers, now published in Cancer Chemotherapy and Pharmacology.
One of the most striking findings: actionable DPYD variants were about 10-fold less frequent in admixed Mexican populations than in European-ancestry populations. This matters because many current pharmacogenetic tests and dosing recommendations are based largely on European-derived data. Our results suggest that the variants and algorithms we currently use may not translate equally well to admixed populations – an important consideration as we work toward truly equitable precision medicine.
First author Vanessa Gonzalez-Covarrubias led the genomic analysis and work behind this study at Instituto Nacional de Medicina Genómica. We also had outstanding coauthors in Andrea Morales-Alfaro, Oscar Bonilla-Jimenez, Mauricio Rodríguez-Dorantes, and Emmanuel Frías-Jimenez.
You can read it for free here.
This work was supported by a Research Foundation Disparities Grant from the American Gastroenterological Association (AGA).
More diverse populations in pharmacogenomic research are not just desirable — they are necessary if precision medicine is going to be precise for everyone.”
Title: Characterization of DPYD pharmacogenetic variation in Mexican patients with gastrointestinal malignancies
Authors: Vanessa Gonzalez-Covarrubias, Andrea Morales-Alfaro, Oscar Bonilla-Jimenez, Mauricio, Rodríguez-Dorantes, Emmanuel Frías-Jimenez, Enrique Soto-Perez-de-Celis
Read the full article here.
You may also be interested in: 10 Must-Read Posts In GI Oncology This Week
